Volume 10 Issue 3, June 2016

The Center for Research and Advanced Studies (Cinvestav) is a national leader in scientific research, technology development and the formation of highly educated professionals in Mexico. Cinvestav is now expanding its reach globally with a nanoparticle-based therapy for Parkinson’s disease that represents an opportunity for international partnerships.

By translating academic innovation and partnering with big pharma, the University of Dundee’s Drug Discovery Unit (DDU) is developing novel therapeutic targets to a stage where they can be smoothly transitioned across to the pharmaceutical industry.

The National Institute of Allergy and Infectious Diseases’ (NIAID) Technology Transfer and Intellectual Property Office (TTIPO) has been instrumental in advancing innovation, continuously building on the institute’s record of scientific excellence with its partners.

Combining its heritage in innovation with capabilities in clinical translational medicine, Ulster University has created a pipeline of promising licensing opportunities that target a number of therapeutic areas.

Through its nimble Office of Therapeutics Alliances, NYU Langone Medical Center is harnessing the therapeutic potential of its world-class research by partnering with external experts in commercial drug discovery and development to advance the next generation of medical therapies and diagnostics.

How scale and a translational ethos enable effective collaborations.

CALYM is a nonprofit research institute that offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international phase 3 clinical trials.

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, is a first-of-its-kind international center for research on and development of microbial and mammalian-cell–based production platforms.

Global viral threats such as Ebola and Zika have accelerated vaccine developers’ forays into public health and catalyzed new partnership strategies.

Recognizing that even broad, multidisciplinary teams need external support, GSK has formed over 115 partnerships to help develop vaccines for the future.

By mimicking the way viruses bind to host cells, NanoViricides is developing unique nanomedicines that are able to trick, trap and destroy these pathogens.

Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.

Motif Bio’s iclaprim shows rapid bactericidal activity and low propensity for induction of resistance and is in late-stage clinical testing for acute bacterial skin and skin structure infections.

The Antibody Lab is launching BESTcell, a new system to make fast, stable mammalian cells for bioproduction.

Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.

Now ready for partnering, Biotest’s IgM Concentrate could be a breakthrough therapy for patients with severe community-acquired pneumonia.

With two marketed products, two successful technology platforms and two advanced clinical candidates, Valneva is fast becoming the leading independent vaccine company.

The pharmaceutical and biotechnology industries see over 3,000 deals signed every year, many of which involve the complex and often unfamiliar process of valuing potential products that are not yet on the market. In this feature, valuation specialists Venture Valuation explain how the value of a product is calculated and how this relates to the overall deal value.

d3 Medicine challenges conventional dogmatic approaches and achieves unprecedented accelerated development pathways.

Aeglea Biotherapeutics is engineering human enzymes as replacement therapies for the treatment of both inborn errors of metabolism and cancer.

Verseon’s unique computational platform is driving the identification and optimization of novel drug candidates for a broad range of indications.

New biotech company Lantern Pharma is leading a wave of innovation in cancer treatment by bringing the best therapies to the patients who are most likely to respond.

Recently announced inflammation deals selected by BioPharma Dealmakers highlight the approaches companies are taking to target disorders in this area, specifically those affecting the gastrointestinal system.

Leveraging an innovative discovery platform, Curileum Discovery is developing an approach based on stem cell drugs that has the potential to cure a wide range of gastrointestinal disorders.

Anatabine citrate, a cholinergic small molecule in development at Rock Creek Pharmaceuticals, offers a distinct alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and biologics for the treatment of chronic and acute inflammatory diseases. The company is looking to partner for a phase 2 trial in psoriasis.